share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  07/16 17:33
Moomoo AI 已提取核心訊息
On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.
On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.
2024年7月16日，60 Degrees Pharmaceuticals, Inc.虛擬進行了其2024年股東大會。在會議期間，以約51.86％的優先投票股份進行了法定人數的確認。五名董事候選人當選，任期至2025年年度股東大會。此外，股東批准修改了2022年股權激勵計劃，將發行可用股票數量增加了500萬。普通股的反向股票拆分也獲得批准，比例區間爲1:5至1:12，由董事會確定。爲遵守納斯達克上市規則5635(c)條款，批准了對CEO和CFO期權行權價格的修改，以及向顧問發行期權。此外，RBSm LLP被確認爲截至2024年12月31日的獨立核數師。會議以所有提案獲得代表股份所需多數批准而結束。
2024年7月16日，60 Degrees Pharmaceuticals, Inc.虛擬進行了其2024年股東大會。在會議期間，以約51.86％的優先投票股份進行了法定人數的確認。五名董事候選人當選，任期至2025年年度股東大會。此外，股東批准修改了2022年股權激勵計劃，將發行可用股票數量增加了500萬。普通股的反向股票拆分也獲得批准，比例區間爲1:5至1:12，由董事會確定。爲遵守納斯達克上市規則5635(c)條款，批准了對CEO和CFO期權行權價格的修改，以及向顧問發行期權。此外，RBSm LLP被確認爲截至2024年12月31日的獨立核數師。會議以所有提案獲得代表股份所需多數批准而結束。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息